Pursuant to section 10(d) of the Federal Advisory Committee Act, as Start Printed Page 26056amended (5 U.S.C. App.), notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis Panel; Development of Anticancer Agents.
Date: May 23, 2013.
Time: 11:30 a.m. to 3:30 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Cancer Institute, Shady Grove West Tower, 9609 Medical Center Drive, Room 7W032, Rockville, MD 20850 (Telephone Conference Call).
Contact Person: Joyce C. Pegues, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, 9609 Medical Center Dr., Room 7W248, Bethesda, MD 20892-975, 240-276-6375, firstname.lastname@example.org.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)
Dated: April 29, 2013.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2013-10451 Filed 5-2-13; 8:45 am]
BILLING CODE 4140-01-P